Andelyn Biosciences to Implement Curator® Platform to Develop and Manufacture Gene Therapy AAV9-GM2 for Queen's University to Treat GM2 Gangliosidoses

PartnershipAAV9-GM2Positive

AI Analysis

Summary

Andelyn Biosciences has partnered with Queen's University to develop and manufacture AAV9-GM2, a gene therapy candidate for treating GM2 Gangliosidoses, utilizing Andelyn's Curator® platform.

Importance:5/10

Sentiment:

0.50

gene therapyAAV9CDMOmanufacturingpartnershiprare disease

Read the original article

Published by PR Newswire Biotech on August 18, 2026 5:21 PM

Read Original